Skip to Content

Aldeyra Therapeutics, Inc.

Securities Class Action

  • Date:
  • 5/29/2026
  • Company Name:
  • Aldeyra Therapeutics, Inc.
  • Stock Symbol:
  • ALDX
  • Class Period:
  • FROM 11/3/2023 TO 3/16/2026
  • Status:
  • Filed
  • Filing Date:
  • 3/30/2026
  • Court:
  • U.S. District Court: Massachusetts

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Aldeyra securities between November 3, 2023 and March 16, 2026, both dates inclusive (the “Class Period”). Investors have until May 29, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 
The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Aldeyra’s business, operations, and prospects, including allegations that: (1) the results of the reproxalap clinical trials were inconsistent; and (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful.
 
If you purchased or otherwise acquired Aldeyra shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aldeyra Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: